CA3129755A1 - Method for treating preeclampsia - Google Patents

Method for treating preeclampsia Download PDF

Info

Publication number
CA3129755A1
CA3129755A1 CA3129755A CA3129755A CA3129755A1 CA 3129755 A1 CA3129755 A1 CA 3129755A1 CA 3129755 A CA3129755 A CA 3129755A CA 3129755 A CA3129755 A CA 3129755A CA 3129755 A1 CA3129755 A1 CA 3129755A1
Authority
CA
Canada
Prior art keywords
antithrombin
preeclampsia
administration
mmhg
pregnancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129755A
Other languages
English (en)
French (fr)
Inventor
Yoshihide Nakamura
Takashi Murayama
Kenichi Takagi
Ryutaro Shimazaki
Yuichi Endo
Hironori Kanda
Kayoko Motoyama
Masaya Kato
Shunichiro Orihara
Tomoko Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of CA3129755A1 publication Critical patent/CA3129755A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3129755A 2019-02-11 2020-02-10 Method for treating preeclampsia Pending CA3129755A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962803888P 2019-02-11 2019-02-11
US62/803,888 2019-02-11
US201962820459P 2019-03-19 2019-03-19
US62/820,459 2019-03-19
PCT/JP2020/005130 WO2020166557A1 (ja) 2019-02-11 2020-02-10 妊娠高血圧腎症の治療方法

Publications (1)

Publication Number Publication Date
CA3129755A1 true CA3129755A1 (en) 2020-08-20

Family

ID=72044881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129755A Pending CA3129755A1 (en) 2019-02-11 2020-02-10 Method for treating preeclampsia

Country Status (7)

Country Link
US (1) US20220202920A1 (cg-RX-API-DMAC7.html)
EP (1) EP3925616A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2020166557A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020222120A1 (cg-RX-API-DMAC7.html)
CA (1) CA3129755A1 (cg-RX-API-DMAC7.html)
TW (1) TW202045203A (cg-RX-API-DMAC7.html)
WO (1) WO2020166557A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210070933A (ko) 2019-12-05 2021-06-15 주식회사 엘지에너지솔루션 리튬 이차전지용 양극 활물질, 상기 양극 활물질의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07316072A (ja) * 1994-05-24 1995-12-05 Green Cross Corp:The 妊娠中毒症治療剤
CN1890262B (zh) 2003-10-09 2015-01-28 协和发酵麒麟株式会社 抗凝血酶ⅲ组合物的制造方法
WO2008120801A1 (ja) 2007-04-02 2008-10-09 Kyowa Hakko Kirin Co., Ltd. アンチトロンビン組成物の製造方法
WO2016159204A1 (ja) * 2015-03-31 2016-10-06 協和発酵キリン株式会社 アンチトロンビン ガンマを含む治療用組成物

Also Published As

Publication number Publication date
JPWO2020166557A1 (ja) 2021-12-16
EP3925616A4 (en) 2022-12-21
TW202045203A (zh) 2020-12-16
US20220202920A1 (en) 2022-06-30
EP3925616A1 (en) 2021-12-22
WO2020166557A1 (ja) 2020-08-20
JP2023060011A (ja) 2023-04-27
AU2020222120A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
Pistolesi et al. Preventing continuous renal replacement therapy-induced hypophosphatemia: an extended clinical experience with a phosphate-containing solution in the setting of regional citrate anticoagulation
Paidas et al. Prospective, randomized, double-blind, placebo-controlled evaluation of the pharmacokinetics, safety and efficacy of recombinant antithrombin versus placebo in preterm preeclampsia
Poon Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus
US20220202920A1 (en) Method for treating preeclampsia
Tolcher et al. Complications of preeclampsia
CA2492858C (en) Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients
CN1688337B (zh) 用于调节先兆子痫患者和子痫患者的钠/钾三磷酸腺苷酶活性的地高辛免疫fab的用途
US20200147188A1 (en) Therapeutic composition containing antithrombin gamma
Shayanpour et al. Evaluating intradialytic change of serum magnesium and its relation to intradialytic complications in chronic hemodialysis patients during one-month period
US10441631B2 (en) Therapeutic agent for amniotic fluid embolism
RU2438191C1 (ru) Способ коррекции гипоэстроген-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
Jelliffe et al. 104: Metformin prevents preeclampsia in an obese mouse model of soluble FMS-like tyrosine kinase-1 induced pre-eclampsia
FRAKES Oxygen-Carrying Capacity and Delivery
Beard et al. Haemoglobinopathies in immigrant families
Shilpashree Comparison of Maternal Serum Calcium and Magnesium Levels in Preeclampsia and Normal Pregnant Woman
Silberschmid et al. Normal lung function during experimental hemorrhagic shock
Shravya A Clinical Study of Maternaland Perinatal Outcome in Pregnancy Induced Hypertension
Atkinson Probing cardiac metabolism in uraemic cardiomyopathy
McCann The Term Infant
Dollins Part 2: Circulation
Cardin et al. Starvation-Induced Ovine Toxemia: A Re-Evaluation
Jeyabalan et al. in pregnancy
Ferraris et al. 84 Prematurity in Infants Born to Hiv-Seropositive Mothers
Angelkort et al. Hemodilution
JP2000505819A (ja) 製剤製品

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324